

Test Catalog

Diagnostic. Prognostic. Predictive. Predisposition.





BCR-ABL1 Standard p210, p190

Alternative Name

Philadelphia chromosome, BCR-ABL1 Major, BCR-ABL1 Minor, BCR/ABL1 Standard

Methodology

Molecular

Test Description

Real-time RT-PCR for quantitative detection of t(9;22) BCR-ABL1 fusion transcripts that result in major p210 (e13a2 and/or e14a2) or minor p190 (e1a2) fusion proteins with option to add p230 detection (micro or atypical variant). Analytical sensitivity is 0.002% for p210 and 0.005% for p190, depending on quality and quantity of the isolated RNA and absence of interfering substances. Log reduction score and percent abnormal are reported, and longitudinal data will appear as a NeoTRACK Result on the report. Testing is New York approved for p210 and p190 only. p230 testing may be ordered as a reflex if p210 and p190 are negative, or as a stand-alone test, BCR-ABL1 Non-Standard p230. For p230, results are reported as percent abnormal.

Clinical Significance

Useful for diagnosis and monitoring of Philadelphia chromosome-positive cases of CML and ALL. Also useful for monitoring minimal residual disease (MRD) for ALL and AML.

Specimen Requirements

- Bone Marrow: 2 mL EDTA tube. Sodium heparin acceptable.
- Peripheral Blood: 5 mL EDTA tube. Sodium heparin acceptable.

Note: Test is RNA-based, NOT suitable for Freeze & Hold option.

Storage & Transportation

Use cold pack for transport, making sure cold pack is not in direct contact with specimen. Ship same day as drawn whenever possible; specimens <7 days old preferred.

CPT Code(s)*

81206, 81207

Medicare MoIDX CPT Code(s)*

81479

New York Approved

Yes

Level of Service

Global

Turnaround Time	
5 days	
The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole	

responsibility of the billing party.

Please direct any questions regarding coding to the payor being billed.

NeoGenomics Laboratories is a specialized oncology reference laboratory providing the latest technologies, testing partnership opportunities, and interactive education to the oncology and pathology communities. We offer the complete spectrum of diagnostic services in molecular testing, FISH, cytogenetics, flow cytometry, and immunohistochemistry through our nation-wide network of CAP-accredited, CLIA-certified laboratories.

Committed to research as the means to improve patient care, we provide Pharma Services for pharmaceutical companies, in vitro diagnostic manufacturers, and academic scientist-clinicians. We promote joint publications with our client physicians. NeoGenomics welcomes your inquiries for collaborations. Please contact us for more information.

*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party.

Please direct any questions regarding coding to the payor being billed.



9490 NeoGenomics Way Fort Myers, FL 33912

Phone: 239.768.0600/ Fax: 239.690.4237

neogenomics.com

Rev. 050524